The human cytomegalovirus (HCMV) can infect a remarkably broad cell range within its
host, including parenchymal cells and connective tissue cells of virtually any organ and …

Infections with human cytomegalovirus (HCMV) are a major cause of morbidity and mortality
in humans with acquired or developmental deficits in innate and adaptive immunity. In the …

In an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to
everolimus 1.5 mg or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil …

Cytomegalovirus (CMV) is a common herpesvirus infection and stimulates the expansion of
very large numbers of CMV‐specific T cells that reduce the CD 4/CD 8 ratio and suppress …

Human immunodeficiency virus (HIV)–infected adults who take stable antiretroviral therapy
(ART) are at risk for early onset of age-related diseases. This is likely due to a complex …

Despite remarkable advances in the diagnostic and therapeutic modalities for its
management, cytomegalovirus (CMV) remains one of the most important pathogens …

The evolution of immunosuppression for organ transplantation has reduced the incidence of
acute graft rejection but has increased the risk for infection and virally mediated malignancie …

The recent approval of letermovir marks a new era of therapy for human cytomegalovirus
(HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem …

Intravenous immunoglobulin products (IVIG) are derived from pooled human plasma from
thousands of donors and have been used for the treatment of primary immunodeficiency …

Human cytomegalovirus (HCMV) has been routinely isolated from and propagated in vitro in
human embryonic lung fibroblast (HELF) cell cultures, while in vivo it is known to infect …